Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625411 · ClinicalTrials.gov registry record · Phase 3
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
A Phase 3 study of Thyroid Eye Disease, sponsored by Viridian Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
- 20
- Study locations
NCT06625411: Active Phase 3 study of Thyroid Eye Disease, sponsored by Viridian Therapeutics.
NCT06625411 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Viridian Therapeutics. The registered enrollment target is 117 participants, above the 99-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625411, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Viridian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Primary Outcome
Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the most proptotic eye as measured by exophtalmometer \[without a corresponding increase of ≥2 mm in the other eye\]
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VRDN-003
Study Locations (20)
California
- Alliance Research Institute - Canoga Park - Canoga Park
- Marvel Clinical Research - Huntington Beach
- United Medical Research Institute - Inglewood
- Advancing Research International, LLC - Los Angeles
- Roski Eye Institute, Keck School of Medicine, USC - Los Angeles
- Alliance Research Institute - Lynwood - Lynwood
- A.P.J. Office - Newport Beach
- Byers Eye Institute at Stanford University - Palo Alto
- Pasadena Clinical Trials - Pasadena
- Senta Clinic - San Diego
Florida
- C&A Clinical Trials Corp - Cape Coral
- Ilumina Medical Research - Kissimmee
- Med-Care Research - Miami
- Continental Clinical Research - Miami
- Hype Clinical Research LLC - Miami
- Anmed Health Services LLC - Miami
- Sarasota Retina Institute - Sarasota
Arizona
- Scottsdale Clinical Trials - Scottsdale
Georgia
- Agile Clinical Research Trials, LLC - Atlanta
Illinois
- Vision Medical Research - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2026-11-15 |
| Phase | Phase 3 |
What the registry record for NCT06625411 still lists
NCT06625411 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, above the 99-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (18% higher).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06625411 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06625411 about?
NCT06625411 is a clinical study titled "An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)". This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
What is the current status of trial NCT06625411?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2024-08-27. Estimated completion is 2026-11-15.
What conditions does trial NCT06625411 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06625411?
The interventions under investigation include: Placebo (DRUG), VRDN-003 (DRUG).
Who is sponsoring clinical trial NCT06625411?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625411 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625411's enrollment target sits among peer trials
117 5th of 15 higher than 11 of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI